Insulin-like growth factor (IGF)-I and IGF-binding protein-3 serum levels in relapsing-remitting and secondary progressive multiple sclerosis patients

Lanzillo, Roberta; Somma, Carolina Di; Quarantelli, Mario; Ventrella, Gianluca; Gasperi, Maurizio; Prinster, Anna; Vacca, Giovanni; Pivonello, Claudia; Orefice, G; Colao, Annamaria; Morra, Vincenzo Brescia

doi:10.1111/j.1468-1331.2011.03433.x

Cited by 18 publications

(21 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, Lanzillo and colleagues [2] did not find a difference in IGF-I per se between HC and MS but detected a lower IGF-I/IGFBP-3 ratio in MS compared with controls. Interestingly, higher levels of IGFBP-3 in more disabled patients (with higher EDSS at 10 years of disease) were found, suggesting the reduced bioavailability of IGF-I (more than a lower IGF-I level) as a possible pathogenetic factor.…”

Section: Discussionmentioning

confidence: 99%

“…Remyelination is largely known to occur in MS [1], but it is still unclear why its adequacy differs so largely among patients. Many factors have been proposed to influence remyelination, including several neuroendocrine factors [2, 3]. Unresponsiveness to these factors and/or their insufficient release could possibly be involved in reparative mechanism failure, and studies focusing on these molecules have attracted a great deal of attention.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Growth Hormone and Disease Severity in Early Stage of Multiple Sclerosis

Gironi

Solaro²,

Meazza

et al. 2013

Multiple Sclerosis International

View full text Add to dashboard Cite

Evidence suggests that neurohormones such as GH and IGF-I are involved in the neuroreparative processes in multiple sclerosis (MS). GH and IGF-I blood levels in naïve MS patients with different disease courses were investigated in this study. Serum GH and IGF-I in untreated MS patients (n = 64), healthy controls (HC, n = 62), and patients affected by other neurological diseases (OND, n = 46) were evaluated with a solid-phase-enzyme-labeled-chemiluminescent-immunometric assay. No differences were detected in GH across MS, OND, and HC (MS = 0.87 ± 1.32 ng/mL; OND = 1.66 ± 3.7; and HC = 1.69 ± 3.35; P = 0.858) when considering gender, disease duration, and disease course. However, GH was lower (P = 0.007) in patients with more severe disease (expanded disability scale score, EDSS ≥ 4.0) compared with milder forms (EDSS < 4). IGF-I l did not differ across the 3 groups (P = 0.160), as far as concern disease course, disability, and gender were. Lower IGF-I levels were detected in subjects older than 50 years compared to younger ones for all 3 groups. Lower GH was detected in patients with more severe MS, and age was confirmed as the main factor driving IGF-I levels in all subjects. These findings, relying on the natural course of the disease, could help in shedding lights on the mechanisms involved in autoreparative failure associated with poorer prognosis in MS.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Growth Hormone and Disease Severity in Early Stage of Multiple Sclerosis

Gironi

Solaro²,

Meazza

et al. 2013

Multiple Sclerosis International

View full text Add to dashboard Cite

show abstract

“…This inconsistency of IGFBP3 levels in MS patients may be due to the differences of sample size and patients' demographic characteristics. However, IGFBP3 level correlated with disease severity score, relapsing-remitting disease pattern and treatment strategy, indicating the involvement of IGFBP3 in the pathogenesis of MS (67, 69, 70). Serum IGFBP2 was reported to be increased in MS patients compared to healthy control (69).…”

Section: Igfbps As Biomarkers In Autoimmune Diseasesmentioning

confidence: 97%

“…Consistent with this, IGFBP1 as well as IGFBP6 were proven to be overexpressed in oligodendrocytes at the edges of demyelinated plaques, indicating a pathogenic role of them in the development of MS (66). Other studies focused on the serum concentration of IGFBP3 in MS, but the results lacked consistency (67–70). This inconsistency of IGFBP3 levels in MS patients may be due to the differences of sample size and patients' demographic characteristics.…”

Section: Igfbps As Biomarkers In Autoimmune Diseasesmentioning

confidence: 99%

Insulin-Like Growth Factor Binding Proteins in Autoimmune Diseases

Ding

2018

Front. Endocrinol.

View full text Add to dashboard Cite

Insulin-like growth factor binding proteins (IGFBPs) are a family of proteins binding to Insulin-like growth factors (IGFs), generally including IGFBP1, IGFBP2, IGFBP3, IGFBP4, IGFBP5, and IGFBP6. The biological functions of IGFBPs can be classified as IGFs-dependent actions and IGFs-independent effects. In this review, we will discuss the structure and function of various IGFBPs, particularly IGFBPs as potential emerging biomarkers and therapeutic targets in various autoimmune diseases, and the possible mechanisms by which IGFBPs act on the pathogenesis of autoimmune diseases.

show abstract

“…This state in MS suggests that the IGF system is an important player in MS disease. On the other hand, circulating IGF-I levels in the serum and CSF are not different in MS patients when they are compared to control (Pirttila et al 2004, Poljakovic et al 2006, Wilczak et al 2005), although the IGFBP-3 levels are increased in MS patient serum, which may account for reduced bioavailability of IGF-I (Lanzillo et al 2011). …”

Section: Growth Factors Known To Impact Oligodendrocytes In Demyelmentioning

confidence: 99%

The role of growth factors as a therapeutic approach to demyelinating disease

Huang

Dreyfus

2016

Experimental Neurology

View full text Add to dashboard Cite

A variety of growth factors are being explored as therapeutic agents relevant to the axonal and oligodendroglial deficits that occur as a result of demyelinating lesions. This review focuses on five such proteins that are present in the lesion site and impact oligodendrocyte regeneration. It then presents approaches that are being exploited to manipulate the lesion environment affiliated with multiple neurodegenerative diseases and suggests that the utility of these approaches can extend to demyelination. Challenges are to further understand the roles of specific growth factors on a cellular and tissue level. Emerging technologies can then be employed to optimize the use of growth factors to ameliorate the deficits associated with demyelinating degenerative diseases.

show abstract

Insulin-like growth factor (IGF)-I and IGF-binding protein-3 serum levels in relapsing-remitting and secondary progressive multiple sclerosis patients

Cited by 18 publications

References 18 publications

Growth Hormone and Disease Severity in Early Stage of Multiple Sclerosis

Growth Hormone and Disease Severity in Early Stage of Multiple Sclerosis

Insulin-Like Growth Factor Binding Proteins in Autoimmune Diseases

The role of growth factors as a therapeutic approach to demyelinating disease

Contact Info

Product

Resources

About